SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
DURHAM, N.C., March 09, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Founder and Chief Executive Officer, will present at the 29th Annual ROTH Conference in Newport Beach, CA on Monday, March 13, 2017, at 5:30 p.m. Pacific Time.
The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
Contact: Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
